Biogen Explains How Its Alzheimer’s Drug Went From Poor to Promising

It doesn’t happen often—in fact, hardly ever—that a company decides to stop studying a promising drug it’s developing and then a few months later asks the Food and Drug Administration (FDA) to consider approving it. But that’s exactly what occurred with aducanumab, an Alzheimer’s drug being developed by U.S. pharmaceutical company Biogen and its partner, … Read more

AI Can Now Make Medical Predictions from Raw Data. But Can Deep Learning Be Trusted?

—In clinics around the world, a type of artificial intelligence called deep learning is starting to supplement or replace humans in common tasks such as analyzing medical images. Already, at Massachusetts General Hospital in Boston, “every one of the 50,000 screening mammograms we do every year is processed through our deep learning model, and that … Read more